7 completed. 4 Phase 3, 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow SEP 225289: new trials by email Literature Review of SEP 225289 trials Research Report on SEP 225289
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. dasotraline, Placebo - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 95 | 2017-07-31 | 2020-07-08 |
| A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder dasotraline 4mg, dasotraline 6mg, Placebo - Binge Eating Disorder | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 491 | 2017-03-31 | 2020-07-13 |
| Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction dasotraline - Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 44 | 2016-05-01 | 2016-12-02 |
| A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. dasotraline 4mg, Placebo - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 132 | 2016-04-30 | 2020-03-27 |
| Dasotraline Pediatric ADHD Study Dasotraline, Placebo Comparator - Attention Deficit Hyperactivity Disorder | Phase 2 / Phase 3 | Completed | Sumitomo Pharma America, Inc. | 330 | 2015-04-01 | 2021-03-18 |
| Adult Attention Deficit Hyperactivity Disorder SEP-225289, Placebo - Adult Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 341 | 2012-12-01 | 2015-01-12 |
| A Safety, Efficacy and Tolerability Study of SEP-225289 SEP-225289, Venlafaxine, placebo - Depressive Disorder, Major | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 523 | 2007-12-01 | 2012-02-23 |
Attention Deficit Disorder with Hyperactivity (5) · Binge-Eating Disorder (2) · Depression (1) · Depressive Disorder, Major (1) · Dysthymic Disorder (1) · Mental Disorders (1) · Mood Disorders (1)
Sumitomo Pharma America, Inc. (7)
United States (7)